ライフサイエンスコーパス: human immunoglobulin

1 eutralizing titer with pooled plasma-derived human immunoglobulin.

2 s treated contemporaneously with nonspecific human immunoglobulin.

3 he B7-CD28 costimulatory pathway, or control human immunoglobulin (200 microg) on the day of transpla

4 Human immunoglobulin A (IgA) is an abundant antibody tha

5 BCP also binds human immunoglobulin A (IgA), a characteristic that may

6 al, in that it exhibited specific binding to human immunoglobulin A (IgA), IgD, and IgG in addition t

7 Components of the human immunoglobulin A1 (IgA1) hinge governing sensitivi

8 a zinc metalloproteinase, Iga, which cleaves human immunoglobulin A1 (IgA1), and whose activity is pr

9 crete site-specific proteases able to cleave human immunoglobulin A1 (IgA1), the first line of defens

10 ococcus expresses a protease that hydrolyzes human immunoglobulin A1 (IgA1).

11 Human immunoglobulin administered intraperitoneally at t

12 o the human HAVCR1/TIM1 Fc contained cDNA of human immunoglobulin alpha 1 heavy (Igalpha1) and lambda

13 e application of the new method by analyzing human immunoglobulin and Drosophilid alcohol dehydrogena

14 assessed by change in levels of circulating human immunoglobulins and by histologic examinations.

15 , which is confirmed by depletion studies of human immunoglobulins and by mouse immunizations.

16 omponents were confirmed by the detection of human immunoglobulins and human interleukin-6 in serum s

17 are detected with fluorescently labeled anti-human immunoglobulin antibody and flow analysis in a dua

18 donkeys, rats, and mice) and the binding to human immunoglobulins appears to be immunoglobulin G (Ig

19 mmunoglobulins and rabbit antibodies against human immunoglobulins, but not into immunoprecipitates f

20 Within 25 kb downstream of both the human immunoglobulin Calpha1 and Calpha2 genes we identi

21 the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indic

22 MK2-23 variable regions covalently linked to human immunoglobulin constant regions enhanced mAb MK2-2

23 Human immunoglobulin D (IgD) occurs most abundantly as a

24 ed the ability of this mutant strain to bind human immunoglobulin D.

25 cs and a T cell-expansion system to identify human immunoglobulin-derived peptides capable of inducin

26 vide novel insight into the action of pooled human immunoglobulin during invasive S. pyogenes infecti

27 d by detecting human immunoglobulin G (IgG), human immunoglobulin E (IgE) and Aspergillus fumigatus a

28 biosensor, featuring a highly specific anti-human immunoglobulin E (IgE) aptamer as a capture probe,

29 aptamer-based biosensor for the detection of human immunoglobulin E (IgE) is developed using the elec

30 The human immunoglobulin E antibody responses to the group 1

31 d in the A-B loop of the Cepsilon3 domain of human immunoglobulin E has been carried out.

32 o extend the concept to humans, we immunized human immunoglobulin-expressing mice with human DEC205 (

33 was immunocaptured by immobilized goat anti-human immunoglobulin Fc(gamma) antibody resin, and the c

34 d MAPs were found in a preparation of normal human immunoglobulin for intravenous use.

35 An obtained scFv was converted into human immunoglobulin formats including IgE.

36 aluate the efficacy of a soluble murine RANK-human immunoglobulin fusion protein (muRANK.Fc) as a bon

37 nd-analyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobu

38 ngle-wall carbon nanotubes (SWCNTs) and anti-human immunoglobulin G (anti-HIgG) is reported herein.

39 itive binding proteins for the Fc portion of human immunoglobulin G (hIgG) (hFc) using two different

40 Control samples containing a nonspecific human immunoglobulin G (hIgG) antibody were also studied

41 onitor and characterize the AGE formation of human immunoglobulin G (hIgG) by MG and G using ultravio

42 -1) virions and HSV-1-infected cells bind to human immunoglobulin G (hIgG) via its Fc region.

43 anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG).

44 In an in vitro neutralization assay using human immunoglobulin G (IgG) (intravenous immune globuli

45 Group 2 mice were actively immunized with human immunoglobulin G (IgG) anti-cardiolipin antibodies

46 orescence of an immunoassay of Protein A and human immunoglobulin G (IgG) by over 7400-fold and the i

47 resenting amino acids 106 to 138 of CAP18 to human immunoglobulin G (IgG) by using the heterobifuncti

48 domains of growth factor receptors fused to human immunoglobulin G (IgG) Fc were incubated with para

49 cells (IPEC) were incubated with polyclonal human immunoglobulin G (IgG) for 6 days before incubatio

50 We used pooled human immunoglobulin G (IgG) from HIV-negative donors to

51 ate neutralization, a panel of 12 anti-HIV-1 human immunoglobulin G (IgG) MAbs, specific for epitopes

52 Heat maps for human immunoglobulin G (IgG) responses for each village

53 the efficacies of anti-GXM MAbs of the four human immunoglobulin G (IgG) subclasses, which have iden

54 In this study, human immunoglobulin G (IgG) that had previously been sh

55 We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antib

56 immunosensor for the sensitive detection of human immunoglobulin G (IgG) was prepared based on gold

57 Three-dimensional (3D) ordered arrays of human immunoglobulin G (IgG) were fabricated using well-

58 Enzymatically released N-glycans from human immunoglobulin G (IgG) were used as the test sampl

59 y of APPmicroTP is demonstrated by detecting human immunoglobulin G (IgG), human immunoglobulin E (Ig

60 in vitro, in the presence of high levels of human immunoglobulin G (IgG), in the serum of patients r

61 has cysteine endopeptidase activity against human immunoglobulin G (IgG).

62 ntly linked to human serum albumin (HSA) and human immunoglobulin G (IgG).

63 orption is reported for selective binding of human immunoglobulin G (IgG).

64 ressed, the genes encode proteins which bind human immunoglobulin G (Mrp50 and EmmL50) or immunoglobu

65 Multiplexed assay of human immunoglobulin G and M (IgG and IgM) antibodies wi

66 e designed our assay using a monoclonal anti-human immunoglobulin G antibody bound to the solid phase

67 A significantly higher human immunoglobulin G antibody response and the highest

68 east 3 Gag peptides, and high titers of anti-human immunoglobulin G antibody were made.

69 acterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.

70 rminal to the heavy-chain constant region of human immunoglobulin G containing the Fc receptor bindin

71 ibited by the addition of a Fc-specific anti-human immunoglobulin G Fab fragment to the virus-antibod

72 se cleavage site that, in turn, is linked to human immunoglobulin G Fc.

73 Recent advances enabling the cloning of human immunoglobulin G genes have proven effective for d

74 Picomolar detection of human immunoglobulin G has been realized using particle

75 the extracellular part of layilin joined to human immunoglobulin G heavy chain and used this chimera

76 ed as a fusion product with the Fc domain of human immunoglobulin G heavy chain gamma1 (gB-Fc) in an

77 The hinge region on the Fc fragment of human immunoglobulin G interacts with at least four diff

78 Human immunoglobulin G isotype 4 (IgG4) antibodies (Abs)

79 Binding studies with polyclonal human immunoglobulin G suggest that the antibody respons

80 um samples from vaccinated animals contained human immunoglobulin G that reacted with HIV-1 Env prote

81 IL-17R:Fc or control human immunoglobulin G was administered i.p. (500 microg

82 Rituximab, a chimeric human immunoglobulin G(1) (IgG(1)) anti-CD20 monoclonal

83 of a model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a vi

84 detection 10ng/ml) and selectivity towards human immunoglobulin G.

85 detection ~10ng/ml) and selectivity towards human immunoglobulin G.

86 ine serum albumin, and high-molecular weight human immunoglobulin G.

87 receptors 1 and 2 fused to the Fc portion of human immunoglobulin G.

88 single-cell cloning and expression of fully human immunoglobulin-G.

89 he BZLF2 protein linked to the Fc portion of human immunoglobulin G1 (BZLF2.Fc) was expressed from ma

90 The quantitative analysis of human immunoglobulin G1 (hIgG1) by mass spectrometry is

91 ype forms of obinutuzumab, particularly when human immunoglobulin G1 (hIgG1) mAbs were compared.

92 R) (p80) domains linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc).

93 Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody tar

94 age display library to generate IMC-41A10, a human immunoglobulin G1 (IgG1) antibody that binds with

95 Human immunoglobulin G1 (IgG1) contains 12 domains, and

96 racellular domain fused to the Fc portion of human immunoglobulin G1 (IgG1), and growth factors stem

97 clinical trials are chimeric, humanized, and human immunoglobulin G1 (IgG1).

98 ed with ACI blood (RT1a) together with L6 (a human immunoglobulin G1 [IgG1] antibody as isotype contr

99 requires priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L

100 d #8 CLL clones were prepared as recombinant human immunoglobulin G1 and used as primary antibodies i

101 Ramucirumab is a human immunoglobulin G1 antibody that binds vascular end

102 An Fn14-specific blocking human immunoglobulin G1 antibody variant with compromise

103 mmaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent c

104 tumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody.

105 citumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that co

106 ted was then recombinantly engineered with a human immunoglobulin G1 Fc region to construct the fully

107 ropic envelope protein to the Fc region of a human immunoglobulin G1 molecule for use in binding assa

108 irus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at

109 We examined here whether a fully human immunoglobulin G1 monoclonal antibody (MAb) specif

110 at and exploiting the stable architecture of human immunoglobulin G1 We used iterative experimental v

111 2b) or its humanized derivative, CAMPATH-1H (human immunoglobulin G1).

112 gle-chain Fv antibody fragments fused to the human immunoglobulin G1-derived Fc fragment under the co

113 ain was fused in frame with the Fc domain of human immunoglobulin G1.

114 ke domain of MHVR fused to the Fc portion of human immunoglobulin G1.

115 ed disulfide-mediated structural variants of human immunoglobulin G2 (IgG2) antibodies was recently t

116 ilized hybridoma technology to produce fully human immunoglobulin G2 (IgG2) MAbs from B cells of an i

117 Human immunoglobulin G2 (IgG2) responses are gamma inter

118 Human immunoglobulin G2 (IgG2) serum concentrations and

119 ized by Dob1, which is a hybridoma-secreting human immunoglobulin G2 antibody to the PS of serotype 6

120 The anti-PS human immunoglobulin G2 MAb made from mice immunized wit

121 onjugate glembatumumab vedotin links a fully human immunoglobulin G2 monoclonal antibody against the

122 Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds t

123 Panitumumab (P) is a fully human, immunoglobulin G2 monoclonal antibody targeting e

124 ace molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumo

125 Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkp

126 Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkp

127 Nivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkp

128 Nivolumab, a human immunoglobulin G4-blocking antibody against the T-

129 sence of histidine also enhanced cleavage of human immunoglobulin gamma (IgG) molecules containing a

130 relation with SEC and can be applied to both human immunoglobulin gamma 1 (IgG1) and IgG2 antibodies.

131 he large cleavage product of Pref-1 fused to human immunoglobulin-gamma constant region.

132 We further tested these programs using 30 human immunoglobulin genes from Genbank and here highlig

133 Mice transgenic for human immunoglobulin genes were immunized with OspA from

134 Transgenic mice with human immunoglobulin genes were immunized with the recom

135 Transgenic mice carrying human immunoglobulin genes were used to isolate HuMAbs t

136 tion sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conser

137 Amplification of human immunoglobulin has many potential applications suc

138 ome vector carrying the entire unrearranged, human immunoglobulin heavy (hIGH) and kappa-light (hIGK)

139 Transgenic mice have been created that carry human immunoglobulin heavy and light chain genes in germ

140 mbinatorial phage display library expressing human immunoglobulin heavy and light chain variable regi

141 re we describe a method for amplification of human immunoglobulin heavy and light chains from single

142 o elk-1-related processed pseudogenes in the human immunoglobulin heavy chain (IgH) locus, accounting

143 d a distinct RNA transcriptome signature and human immunoglobulin heavy chain (VH) repertoire that wa

144 ucleotide 5'non-coding region (5'NCR) of the human immunoglobulin heavy chain binding protein (BiP) m

145 The 5'-non-translated regions (5'NTR) of human immunoglobulin heavy chain binding protein (BiP),

146 To investigate regulation of human immunoglobulin heavy chain expression, we have clo

147 n vivo interaction of these factors with the human immunoglobulin heavy chain gene enhancer regions i

148 The human immunoglobulin heavy chain locus contains 39 funct

149 The highly repetitive human immunoglobulin heavy chain sequence was analyzed u

150 f the IL-4 response element derived from the human immunoglobulin heavy-chain germ line epsilon promo

151 fic immunoglobulin, 111In-labeled polyclonal human immunoglobulin (HIG) was separately administered t

152 e glycoproteins, and a high-titer anti-HIV-1 human immunoglobulin (HIVIG) preparation for their abili

153 VlacZ with coadministration of 200 microg of human immunoglobulin (Ig) G or CTLA4Ig by intraperitonea

154 HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against

155 CRISPR-Cas9 technology to edit the mouse and human immunoglobulin (Ig) genes.

156 Transgenic mice bearing unrearranged human immunoglobulin (Ig) heavy and kappa light chain lo

157 ppropriate precursors in mice transgenic for human immunoglobulin (Ig) loci.

158 hnology, XenoMouse, that contains 80% of the human immunoglobulin (Ig) variable gene repertoire and c

159 y was to determine the antiviral efficacy of human immunoglobulin (Ig), a preparation of highly purif

160 Human immunoglobulin (Ig)A exists in blood as two isotyp

161 osolic domains each mediated rapid uptake of human immunoglobulin (Ig)G followed by recycling of inta

162 The release kinetics for human immunoglobulin (IgG) through the permeable structu

163 albumin (BSA), transferrin factor (TF), and human immunoglobulins (IgG) are utilized as exemplary sa

164 ell development and to support production of human immunoglobulins (Igs), major differences in the ef

165 We have investigated the effect of human immunoglobulin in an animal model of Guillain-Barr

166 Importantly, passive transfer of pooled human immunoglobulin into mice does not interfere with t

167 Human immunoglobulin is an effective treatment for Guill

168 Pooled human immunoglobulin is widely advocated as an adjunctiv

169 we moved to a therapy based on IgM-enriched human immunoglobulins (IVIG), repeated every 4 weeks, an

170 We recently completed a map of the human immunoglobulin lambda (IGL) locus on chromosome 22

171 Host targets, including human immunoglobulin lambda locus (IGL), cytochrome c ox

172 ing 15 functional Vlambda segments) from the human immunoglobulin lambda locus.

173 eins by studying the effects of mutations of human immunoglobulin light chain variable domain (V(L)).

174 (H-D) exchange rates) and the propensity of human immunoglobulin light chains to form amyloid fibril

175 discriminating between benign and pathologic human immunoglobulin light chains.

176 nformational dynamics of a pathogenic kappa4 human immunoglobulin light-chain variable domain, SMA, a

177 Here we report the crystal structure of the human immunoglobulin-like NK cell receptor KIR2DL2 in co

178 l with or without CpG to mice transgenic for human immunoglobulin loci (XenoMouse mice) and expressin

179 ated from transgenic mice reconstituted with human immunoglobulin loci (XenoMouse mice) vaccinated wi

180 ce and transchromosomic (Tc) cattle carrying human immunoglobulin loci are too low for therapeutic ap

181 nic mice with large portions of unrearranged human immunoglobulin loci can produce fully human antige

182 se in mice, by introducing nearly the entire human immunoglobulin loci into the germ line of mice wit

183 sgenic mice reconstituted with megabase-size human immunoglobulin loci to generate a human MAb agains

184 munization via Pfs25 virus-like particles in human immunoglobulin loci transgenic mice.

185 sponse of transgenic mice reconstituted with human immunoglobulin loci, XenoMouse, to PPS antigens in

186 its for the detection of Toxoplasma-specific human immunoglobulin M (IgM) antibodies, an FDA-sponsore

187 Between 5- and 10-fold more purified human immunoglobulin M (IgM) but not IgG was deposited o

188 The human immunoglobulin M (lambda) GXM monoclonal antibody

189 XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and kappa) which wer

190 Immunoglobulin A (IgA), the most abundant human immunoglobulin, mediates immune protection at muco

191 bulin fusion protein (LTbetaR-Ig) or control human immunoglobulin on days embryonic day 11 (E11) and

192 coccal surface proteins recognised by pooled human immunoglobulin permitted identification and rankin

193 Human immunoglobulin preparations for intravenous or sub

194 e platform technology that can produce fully human immunoglobulins rapidly, and in substantial quanti

195 ls but not in unprotected individuals, using human immunoglobulin reactivity data obtained from prote

196 The crystal structure of a human immunoglobulin receptor, FcgammaRIIIb, has been de

197 able to generate a humanized variant using a human immunoglobulin scaffold that shares a high degree

198 Similarly, pooled human immunoglobulin specifically inhibited nuclease act

199 similar fusion protein that, instead, had a human immunoglobulin tail.

200 Antibody VRC01 is a human immunoglobulin that neutralizes about 90% of HIV-1

201 e immunoglobulins are virtually identical to human immunoglobulins, these chimpanzee anticapsid MAbs

202 We describe a novel strain of human immunoglobulin transgenic mice and the use of this

203 Human immunoglobulin transgenic mice provide a method of

204 man antibody response with VH3 expression in human immunoglobulin transgenic mice that has been obser

205 Partitioning the human immunoglobulin variable region into variable (V),

206 onic stem cells, we have inserted the entire human immunoglobulin variable-gene repertoire (2.7 Mb) i

207 The expressed human immunoglobulin Vlambda repertoire demonstrates a s

208 uclease B, human transferrin, and polyclonal human immunoglobulin was rapidly achieved in a few minut

209 e a >300 kDa complex of GB1 with full-length human immunoglobulin, where we found that sample prepara

210 ial got underway to evaluate the efficacy of human immunoglobulin with high titers of antibodies to W